PD Neuroprotection/Mirapex

< PD Neuroprotection

Research

2007

Fedorova & Chigir’ [1] evaluated the use of the dopamine agonist Mirapex in the treatment of P.D.

Improvements were demonstrated in general state, motor activity, daily activities, and the quality of life. Attention is drawn to a decrease in the severity of motor fluctuations and dyskinesias and in anxiety and depression, and to improvements in cognitive functions. The significance of the combination of the high efficacy and good tolerance of this agent is emphasized.

References

  1. ↑ Federova, N.V. and Chigir’, I.P. (2007) Abstract Neurosci. Behav. Physiol. 37 (6) 539-546. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease. http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=pubmed&dopt=AbstractPlus&list_uids=17657423
This article is issued from Wikiversity - version of the Tuesday, August 28, 2012. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.